Kubo Takashi, Akasaka Takashi, Tanimoto Takashi, Takano Masamichi, Seino Yoshitane, Nasu Kenya, Itoh Tomonori, Mizuno Kyoichi, Okura Hiroyuki, Shinke Toshiro, Kotani Jun-Ichi, Ito Shigenori, Yokoi Hiroyoshi, Muramatsu Toshiya, Nakamura Masato, Nanto Shinsuke
Department of Cardiovascular Medicine, Wakayama Medical University, 811-1, Kimiidera, Wakayama, 641-8510, Japan.
Cardiovascular Center, Nippon Medical School, Chiba-Hokusoh Hospital, Chiba, Japan.
Heart Vessels. 2016 Apr;31(4):465-73. doi: 10.1007/s00380-015-0636-6. Epub 2015 Jan 29.
Even in the drug-eluting stent era, diabetes mellitus (DM) patients have high incidences of restenosis and repeat revascularization after percutaneous coronary intervention. The aim of this study was to compare vascular response after stent implantation between sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) by using optical coherence tomography (OCT) in DM patients as well as in non-DM patients. In the Japan-Drug Eluting Stents Evaluation; a Randomized Trial (J-DESsERT), the OCT sub-study enrolled 75 patients who underwent 8 months follow-up imaging after SES or PES implantation. Mean neointimal hyperplasia (NIH) thickness was significantly thinner in SES than PES in the DM group (77 ± 47 vs. 201 ± 114 μm, p < 0.001) and in the non-DM group (84 ± 37 vs. 212 ± 128 μm, p < 0.001). Unevenness of NIH thickness in longitudinal axis was significantly smaller in SES than PES in the DM group (348 ± 191 vs. 726 ± 385 μm, p < 0.001) and in the non-DM group (344 ± 174 vs. 679 ± 314 μm, p < 0.001). The percentage of uncovered struts was significantly greater in SES than PES in the DM group (24 ± 4 vs. 9 ± 14 %, p < 0.001) and in the non-DM group (16 ± 16 vs. 3 ± 4 %, p = 0.002). Compared with PES, SES showed more potent NIH inhibition in DM patients as well as in non-DM patients.
即使在药物洗脱支架时代,糖尿病(DM)患者经皮冠状动脉介入治疗后再狭窄和重复血运重建的发生率仍很高。本研究的目的是通过光学相干断层扫描(OCT)比较糖尿病患者和非糖尿病患者中,西罗莫司洗脱支架(SES)和紫杉醇洗脱支架(PES)植入后血管的反应。在日本药物洗脱支架评估:一项随机试验(J-DESsERT)中,OCT子研究纳入了75例在植入SES或PES后接受8个月随访成像的患者。在糖尿病组中,SES的平均新生内膜增生(NIH)厚度显著薄于PES(77±47 vs. 201±114μm,p<0.001),在非糖尿病组中也是如此(84±37 vs. 212±128μm,p<0.001)。在糖尿病组中,SES的NIH厚度在纵轴上的不均匀性显著小于PES(348±191 vs. 726±385μm,p<0.001),在非糖尿病组中也是如此(344±174 vs. 679±314μm,p<0.001)。在糖尿病组中,SES未覆盖支架的百分比显著高于PES(24±4 vs. 9±14%,p<0.001),在非糖尿病组中也是如此(16±16 vs. 3±4%,p = 0.002)。与PES相比,SES在糖尿病患者和非糖尿病患者中均表现出更强的NIH抑制作用。